Clinical Insights on Hepatotoxicity Associated with Ribociclib in Breast Cancer Patients: A Multi-Center Analysis - Takeaways - MDSpire

Clinical Insights on Hepatotoxicity Associated with Ribociclib in Breast Cancer Patients: A Multi-Center Analysis

  • By

  • Onur Baş

  • Bediz Kurt İnci

  • İmdat Eroğlu

  • Safa Can Efil

  • Seher Kaya

  • Pınar Kubilay Tolunay

  • Taha Koray Şahin

  • Cengiz Karaçin

  • Ozan Yazıcı

  • Mehmet Ali Nahit Şendur

  • Berna Ömür Çakmak Öksüzoğlu

  • Sercan Aksoy

  • November 28, 2025

  • 0 min

Share

  • 1

    Ribociclib significantly improves outcomes for HR+/HER2- breast cancer patients but can cause hepatotoxicity requiring monitoring.

  • 2

    In a study of 845 patients, 9.2% developed hepatotoxicity, with 69.2% experiencing grade 1 toxicity.

  • 3

    Patients with grade 3–4 hepatotoxicity had a decreased overall survival rate compared to those with grade 1–2 toxicity.

  • 4

    The median time to onset of ribociclib-induced hepatotoxicity was 13 weeks after treatment initiation.

  • 5

    The one-year overall survival rate was 90% for grade 1–2 hepatotoxicity and 76% for grade 3–4 hepatotoxicity.

Original Source(s)

Clinical Insights on Hepatotoxicity Associated with Ribociclib in Breast Cancer Patients: A Multi-Center Analysis

  • by Onur Baş, Bediz Kurt İnci, İmdat Eroğlu, Safa Can Efil, Seher Kaya, Pınar Kubilay Tolunay, Taha Koray Şahin, Cengiz Karaçin, Ozan Yazıcı, Mehmet Ali Nahit Şendur, Berna Ömür Çakmak Öksüzoğlu, Sercan Aksoy

  • November 28, 2025

Related Content

Data requirements of an informative, directive, and preventive mobile health application for gastric cancer

High-grade astrocytoma with piloid features: a case report of comprehensive management

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy